Protagonist Therapeutics (NASDAQ:PTGX) Lowered to “Sell” Rating by Wall Street Zen
Wall Street Zen cut shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) from a hold rating to a sell rating in a research report report published on Saturday. A number of other research analysts have also issued reports on PTGX. BMO Capital Markets upped their price target on shares of Protagonist Therapeutics from $62.00 to […]
Wall Street Zen cut shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) from a hold rating to a sell rating in a research report report published on Saturday. A number of other research analysts have also issued reports on PTGX. BMO Capital Markets upped their price target on shares of Protagonist Therapeutics from $62.00 to […]
